SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons

Channels

Volumn 7, Issue 3, 2013, Pages 153-159

  Ju, Weina ^a,b   Li, Qi ^c   Wilson, Sarah M ^d   Brittain, Joel M ^d,f   Meroueh, Louay ^e   Khanna, Rajesh ^a,d  

^a INDIANA UNIVERSITY   (United States)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c Basic Medical College   (China)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Calcium influx; CaV2.2; CRMP2; Sensory neurons; SUMO; Ubc9

Indexed keywords

CALCIUM; CAV2.2 PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; PROTEIN UBC9; PROTEINASE; SENTRIN SPECIFIC PEPTIDASE 1; SENTRIN SPECIFIC PEPTIDASE 2; SUMO 1 PROTEIN; SUMO PROTEIN; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CELL LEVEL; CONJUGATION; CONTROLLED STUDY; ENZYME ACTIVE SITE; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NERVE FIBER GROWTH; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN MODIFICATION; RAT; REGULATORY MECHANISM; SENSORY NERVE CELL; SUMOYLATION;

CALCIUM INFLUX; CAV2.2; CRMP2; SENSORY NEURONS; SUMO; UBC9;

ANIMALS; CALCIUM; CALCIUM CHANNELS; MODELS, MOLECULAR; NERVE TISSUE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SENSORY RECEPTOR CELLS; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMOYLATION;

EID: 84878219010     PISSN: 19336950     EISSN: 19336969     Source Type: Journal    
DOI: 10.4161/chan.24224     Document Type: Article

References (50)

1. Inagaki N, Chihara K, Arimura N, Ménager C, Kawano Y, Matsuo N, et al. CRMP-2 induces axons in cultured hippocampal neurons. Nat Neurosci 2001;4:781-2; PMID:11477421; http://dx.doi.org/10.1038/90476
2. Khanna R, Wilson SM, Brittain JM, Weimer JM, Sultana R, Butterfield AD, et al. Opening Pandors' jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neurons, and central disorders. Future Neurol 2012;5:749-71; http://dx.doi.org/10.2217/fnl.12.68
3. Brittain JM, Piekarz AD, Wang Y, Kondo T, Cummins TR, Khanna R. An atypical role for collapsin response mediator protein 2 (CRMP-2) in neurotransmitter release via interaction with presynaptic voltage-gated calcium channels. J Biol Chem 2009;284:31375-90; PMID: 19755421; http://dx.doi.org/10. 1074/jbc. M109.009951
4. Chi XX, Schmutzler BS, Brittain JM, Wang Y, Hingtgen CM, Nicol GD, et al. Regulation of N-type voltage-gated calcium channels (Cav2.2) and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons. J Cell Sci 2009;122:4351-62; PMID:19903690; http://dx.doi.org/10.1242/jcs.053280
5. Wang Y, Brittain JM, Wilson SM, Khanna R. Emerging roles of collapsin response mediator proteins (CRMPs) as regulators of voltage-gated calcium channels and synaptic transmission. Commun Integr Biol 2010;3:1-4; PMID:20539772; http://dx.doi.org/10.4161/cib.3.2.10620
6. Brittain JM, Wang Y, Eruvwetere O, Khanna R. Cdk5-mediated phosphorylation of CRMP-2 enhances its interaction with CaV2.2. FEBS Lett 2012;586:3813-8; PMID:23022559; http://dx.doi.org/10.1016/j.febslet.2012.09.022
7. Brittain JM, Duarte DB, Wilson SM, Zhu W, Ballard C, Johnson PL, et al. Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca2+ channel complex. Nat Med 2011;17:822-9; PMID:21642979; http://dx.doi.org/10.1038/nm.2345
8. Piekarz AD, Due MR, Khanna M, Wang B, Ripsch MS, Wang R, et al. CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy. Mol Pain 2012;8:54; PMID:22828369; http://dx.doi.org/10.1186/1744-8069-8-54
9. Ripsch MS, Ballard CJ, Khanna M, Hurley JH, White FA, Khanna R. A PEPTIDE UNCOUPLING CRMP-2 FROM THE PRESYNAPTIC Ca (2+) CHANNEL COMPLEX DEMONSTRATES EFFICACY IN ANIMAL MODELS OF MIGRAINE AND AIDS THERAPY-INDUCED NEUROPATHY. Transl Neurosci 2012;3:1-8; PMID:22662308; http://dx.doi.org/10.2478/s13380-012- 0002-4
10. Wilson SM, Schmutzler BS, Brittain JM, Dustrude ET, Ripsch MS, Pellman JJ, et al. Inhibition of transmitter release and attenuation of anti-retroviral-associated and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca2+ channel peptides. J Biol Chem 2012;287:35065-77; PMID:22891239; http://dx.doi.org/10.1074/jbc. M112.378695
11. Wilson SM, Brittain JM, Piekarz AD, Ballard CJ, Ripsch MS, Cummins TR, et al. Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex. Channels (Austin) 2011;5:449-56; PMID:21829088; http://dx.doi.org/10.4161/chan. 5.5.17363
12. Ju W, Li Q, Allette YM, Ripsch MS, White FA, Khanna R. Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide. J Neurochem 2012;124:869-79; PMID:23106100; http://dx.doi.org/10.1111/jnc.12070
13. Brittain JM, Chen L, Wilson SM, Brustovetsky T, Gao X, Ashpole NM, et al. Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2). J Biol Chem 2011;286:37778-92; PMID:21832084; http://dx.doi.org/10.1074/jbc. M111.255455
14. Brittain JM, Pan R, You H, Brustovetsky T, Brustovetsky N, Zamponi GW, et al. Disruption of NMDAR-CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion model. Channels (Austin) 2012;6:52-9; PMID:22373559; http://dx.doi.org/10.4161/chan. 18919
15. Anckar J, Sistonen L. SUMO: getting it on. Biochem Soc Trans 2007;35:1409-13; PMID:18031233; http://dx.doi.org/10.1042/BST0351409
16. Wilkinson KA, Nishimune A, Henley JM. Analysis of SUMO-1 modification of neuronal proteins containing consensus SUMOylation motifs. Neurosci Lett 2008;436:239-44; PMID:18400391; http://dx.doi.org/10.1016/j.neulet.2008.03.029
17. Wilkinson KA, Henley JM. Mechanisms, regulation and consequences of protein SUMOylation. Biochem J 2010;428:133-45; PMID:20462400; http://dx.doi.org/10.1042/BJ20100158
18. Mukhopadhyay D, Dasso M. Modification in reverse: the SUMO proteases. Trends Biochem Sci 2007;32:286-95; PMID:17499995; http://dx.doi.org/10.1016/j. tibs.2007.05.002
19. Müller S, Hoege C, Pyrowolakis G, Jentsch S. SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol 2001;2:202-10; PMID:11265250; http://dx.doi.org/10.1038/35056591
20. Benson MD, Li QJ, Kieckhafer K, Dudek D, Whorton MR, Sunahara RK, et al. SUMO modification regulates inactivation of the voltage-gated potassium channel Kv1.5. Proc Natl Acad Sci U S A 2007;104:1805-10; PMID:17261810; http://dx.doi.org/10.1073/pnas.0606702104
21. Plant LD, Dowdell EJ, Dementieva IS, Marks JD, Goldstein SA. SUMO modification of cell surface Kv2.1 potassium channels regulates the activity of rat hippocampal neurons. J Gen Physiol 2011;137:441-54; PMID:21518833; http://dx.doi.org/10.1085/jgp. 201110604
22. Plant LD, Dementieva IS, Kollewe A, Olikara S, Marks JD, Goldstein SA. One SUMO is sufficient to silence the dimeric potassium channel K2P1. Proc Natl Acad Sci U S A 2010;107:10743-8; PMID:20498050; http://dx.doi.org/10.1073/pnas. 1004712107
23. Raj an S, Plant LD, Rabin ML, Butler MH, Goldstein SA. Sumoylation silences the plasma membrane leak K+ channel K2P1. Cell 2005;121:37-47; PMID:15820677; http://dx.doi.org/10.1016/j. cell.2005.01.019
24. Konopacki FA, Jaafari N, Rocca DL, Wilkinson KA, Chamberlain S, Rubin P, et al. Agonist-induced PKC phosphorylation regulates GluK2 SUMOylation and kainate receptor endocytosis. Proc Natl Acad Sci U S A 2011;108:19772-7; PMID:22089239; http://dx.doi.org/10.1073/pnas.1111575108
25. Westenbroek RE, Hoskins L, Catterall WA. Localization of Ca2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J Neurosci 1998;18:6319-30; PMID:9698323
26. Atlas D. The Voltage-Gated Calcium Channel Functions as the Molecular Switch of Synaptic Transmission. Annu Rev Biochem 2013; PMID:23331239
27. Zamponi GW, Lewis RJ, Todorovic SM, Arneric SP, Snutch TP. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res Rev 2009;60:84-9; PMID:19162069; http://dx.doi.org/10.1016/j.brainresrev. 2008.12.021
28. Park J, Luo ZD. Calcium channel functions in pain processing. Channels (Austin) 2010;4:510-7; PMID:21150297
29. Wilkinson KA, Nakamura Y, Henley JM. Targets and consequences of protein SUMOylation in neurons. Brain Res Rev 2010;64:195-212; PMID:20382182; http://dx.doi.org/10.1016/j.brainresrev. 2010.04.002
30. Merrill JC, Melhuish TA, Kagey MH, Yang SH, Sharrocks AD, Wotton D. A role for non-covalent SUMO interaction motifs in Pc2/CBX4 E3 activity. PLoS One 2010;5:e8794; PMID:20098713; http://dx.doi.org/10.1371/journal.pone.0008794
31. Duprez E, Saurin AJ, Desterro JM, Lallemand-Breitenbach V, Howe K, Boddy MN, et al. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci 1999;112:381-93; PMID:9885291
32. Zhu J, Zhu S, Guzzo CM, Ellis NA, Sung KS, Choi CY, et al. Small ubiquitin-related modifier (SUMO) binding determines substrate recognition and paralogselective SUMO modification. J Biol Chem 2008;283:29405-15; PMID:18708356; http://dx.doi.org/10.1074/jbc. M803632200
33. Perdomo J, Verger A, Turner J, Crossley M. Role for SUMO modification in facilitating transcriptional repression by BKLF. Mol Cell Biol 2005;25:1549-59; PMID:15684403; http://dx.doi.org/10.1128/MCB.25.4.1549-1559.2005
34. Sampson DA, Wang M, Matunis MJ. The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J Biol Chem 2001;276:21664-9; PMID:11259410; http://dx.doi.org/10. 1074/jbc. M100006200
35. Wilson SM, Xiong W, Wang Y, Ping X, Head JD, Brittain JM, et al. Prevention of posttraumatic axon sprouting by blocking collapsin response mediator protein 2-mediated neurite outgrowth and tubulin polymerization. Neuroscience 2012;210:451-66; PMID:22433297; http://dx.doi.org/10.1016/j. neuroscience.2012.02.038
36. Feligioni M, Nishimune A, Henley JM. Protein SUMOylation modulates calcium influx and glutamate release from presynaptic terminals. Eur J Neurosci 2009;29:1348-56; PMID:19344328; http://dx.doi.org/10.1111/j.1460-9568.2009. 06692.x
37. Marangoudakis S, Andrade A, Helton TD, Denome S, Castiglioni AJ, Lipscombe D. Differential ubiquitination and proteasome regulation of Ca (V) 2.2 N-type channel splice isoforms. J Neurosci 2012;32:10365-9; PMID:22836269; http://dx.doi.org/10.1523/JNEUROSCI.0851-11.2012
38. Dorval V, Fraser PE. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J Biol Chem 2006;281:9919-24; PMID: 16464864; http://dx.doi.org/10.1074/jbc. M510127200
39. Takahashi Y, Hasegawa-Moriyama M, Sakurai T, Inada E. The macrophage-mediated effects of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuate tactile allodynia in the early phase of neuropathic pain development. Anesth Analg 2011;113:398-404; PMID:21490083; http://dx.doi.org/10.1213/ANE.0b013e31821b220c
40. Kim C, Jun. K, Lee T, Kim SS, McEnery MW, Chin H, et al. Altered nociceptive response in mice deficient in the alpha (1B) subunit of the voltage-dependent calcium channel. Mol Cell Neurosci 2001;18:235-45; PMID: 11520183; http://dx.doi.org/10.1006/mcne.2001.1013
41. Striessnig J, Koschak A. Exploring the function and pharmacotherapeutic potential of voltage-gated Ca2+ channels with gene knockout models. Channels (Austin) 2008;2:233-51; PMID:18719397; http://dx.doi.org/10.4161/chan. 2.4.5847
42. McGivern JG, McDonough SI. Voltage-gated calcium channels as targets for the treatment of chronic pain. Curr Drug Targets CNS Neurol Disord 2004;3:457-78; PMID:15578964; http://dx.doi.org/10.2174/1568007043336743
43. Cao YQ. Voltage-gated calcium channels and pain. Pain 2006;126:5-9; PMID:17084979; http://dx.doi.org/10.1016/j.pain. 2006.10.019
44. Feliciangeli S, Bendahhou S, Sandoz G, Gounon P, Reichold M, Warth R, et al. Does sumoylation control K2P1/TWIK1 background K+ channels? Cell 2007;130:563-9; PMID:17693262; http://dx.doi.org/10.1016/j.cell.2007.06.012
45. Wang Y, Park KD, Salome C, Wilson SM, Stables JP, Liu R, et al. Development and characterization of novel derivatives of the antiepileptic drug lacosamide that exhibit far greater enhancement in slow inactivation of voltage-gated sodium channels. ACS Chem Neurosci 2011;2:90-106; PMID:21532923; http://dx.doi.org/10.1021/cn100089b
46. Wang Y, Wilson SM, Brittain JM, Ripsch MS, Salomé C, Park KD, et al. Merging Structural Motifs of Functionalized Amino Acids and a-Aminoamides Results in Novel Anticonvulsant Compounds with Significant Effects on Slow and Fast Inactivation of Voltage-gated Sodium Channels and in the Treatment of Neuropathic Pain. ACS Chem Neurosci 2011;2:317-22; PMID:21765969; http://dx.doi.org/10.1021/cn200024z
47. Wang Y, Brittain JM, Jarecki BW, Park KD, Wilson SM, Wang B, et al. In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation. J Biol Chem 2010;285:25296-307; PMID:20538611; http://dx.doi.org/10.1074/jbc. M110.128801
48. Leclere PG, Panjwani A, Docherty R, Berry M, Pizzey J, Tonge DA. Effective gene delivery to adult neurons by a modified form of electroporation. J Neurosci Methods 2005;142:137-43; PMID:15652627; http://dx.doi.org/10.1016/j. jneumeth.2004.08.012
49. Stenmark P, Ogg D, Flodin S, Flores A, Kotenyova T, Nyman T, et al. The structure of human collapsin response mediator protein 2, a regulator of axonal growth. J Neurochem 2007;101:906-17; PMID:17250651; http://dx.doi.org/10.1111/j. 1471-4159.2006.04401.x
50. Bayer P, Arndt A, Metzger S, Mahajan R, Melchior F, Jaenicke R, et al. Structure determination of the small ubiquitin-related modifier SUMO-1. J Mol Biol 1998;280:275-86; PMID:9654451; http://dx.doi.org/10.1006/jmbi.1998.1839